ePrints

The use of daptomycin to treat methicillin-resistant Staphylococcus epidermidis bacteremia in a critically ill child with renal failure

Lookup NU author(s): Katherine Gould, Dr Lee Ferguson

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© Pediatric Pharmacy Advocacy Group. All rights reserved. Daptomycin is excreted primarily unchanged by the kidney. Dosage regimens in children with renal failure remain to be determined. We report the case of an 8-year-old child with multiorgan failure undergoing continuous peritoneal dialysis, successfully treated with intravenous daptomycin for methicillin-resistant Staphylococcus epidermidis bacteremia. A dosage of 8 mg/kg every 48 hour was used. Plasma peak and trough concentrations of daptomycin were 68 mg/L and 14.6 mg/L, respectively, on day 6 of treatment. The dosage regimen achieved daptomycin exposure comparable to that reported in adults undergoing continuous ambulatory peritoneal dialysis and receiving recommended dosages.

Publication metadata

Author(s): Morris S, Gould K, Ferguson LP

Publication type: Article

Publication status: Published

Journal: Journal of Pediatric Pharmacology and Therapeutics

Year: 2017

Volume: 22

Issue: 4

Pages: 300-303

Online publication date: 01/07/2017

Acceptance date: 02/04/2016

ISSN (print): 1551-6776

ISSN (electronic): 2331-348X

Publisher: Pediatric Pharmacy Advocacy Group, Inc.

URL: https://doi.org/10.5863/1551-6776-22.4.300

DOI: 10.5863/1551-6776-22.4.300

Altmetrics

Share